Literature DB >> 16294219

Hemolysis-associated endothelial dysfunction mediated by accelerated NO inactivation by decompartmentalized oxyhemoglobin.

Peter C Minneci1, Katherine J Deans, Huang Zhi, Peter S T Yuen, Robert A Star, Steven M Banks, Alan N Schechter, Charles Natanson, Mark T Gladwin, Steven B Solomon.   

Abstract

During intravascular hemolysis in human disease, vasomotor tone and organ perfusion may be impaired by the increased reactivity of cell-free plasma hemoglobin (Hb) with NO. We experimentally produced acute intravascular hemolysis in a canine model in order to test the hypothesis that low levels of decompartmentalized or cell-free plasma Hb will severely reduce NO bioavailability and produce vasomotor instability. Importantly, in this model the total intravascular Hb level is unchanged; only the compartmentalization of Hb within the erythrocyte membrane is disrupted. Using a full-factorial design, we demonstrate that free water-induced intravascular hemolysis produces dose-dependent systemic vasoconstriction and impairs renal function. We find that these physiologic changes are secondary to the stoichiometric oxidation of endogenous NO by cell-free plasma oxyhemoglobin. In this model, 80 ppm of inhaled NO gas oxidized 85-90% of plasma oxyhemoglobin to methemoglobin, thereby inhibiting endogenous NO scavenging by cell-free Hb. As a result, the vasoconstriction caused by acute hemolysis was attenuated and the responsiveness to systemically infused NO donors was restored. These observations confirm that the acute toxicity of intravascular hemolysis occurs secondarily to the accelerated dioxygenation reaction of plasma oxyhemoglobin with endothelium-derived NO to form bioinactive nitrate. These biochemical and physiological studies demonstrate a major role for the intact erythrocyte in NO homeostasis and provide mechanistic support for the existence of a human syndrome of hemolysis-associated NO dysregulation, which may contribute to the vasculopathy of hereditary, acquired, and iatrogenic hemolytic states.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16294219      PMCID: PMC1283939          DOI: 10.1172/JCI25040

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  55 in total

Review 1.  Nitric oxide's reactions with hemoglobin: a view through the SNO-storm.

Authors:  Mark T Gladwin; Jack R Lancaster; Bruce A Freeman; Alan N Schechter
Journal:  Nat Med       Date:  2003-05       Impact factor: 53.440

2.  Hemoglobin and nitric oxide.

Authors:  Benjamin M Gaston; Joshua M Hare
Journal:  N Engl J Med       Date:  2003-07-24       Impact factor: 91.245

3.  Hemoglobin and nitric oxide.

Authors:  John R Pawloski
Journal:  N Engl J Med       Date:  2003-07-24       Impact factor: 91.245

4.  Effect of fetal hemoglobin on microvascular regulation in sickle transgenic-knockout mice.

Authors:  Dhananjay K Kaul; Xiao-du Liu; Hee-Yoon Chang; Ronald L Nagel; Mary E Fabry
Journal:  J Clin Invest       Date:  2004-10       Impact factor: 14.808

5.  Paroxysmal nocturnal hemoglobinuria: clinical and laboratory studies relating to iron metabolism and therapy with androgen and iron.

Authors:  R C Hartmann; D E Jenkins; L C McKee; R M Heyssel
Journal:  Medicine (Baltimore)       Date:  1966-09       Impact factor: 1.889

6.  Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease.

Authors:  Christopher D Reiter; Xunde Wang; Jose E Tanus-Santos; Neil Hogg; Richard O Cannon; Alan N Schechter; Mark T Gladwin
Journal:  Nat Med       Date:  2002-11-11       Impact factor: 53.440

7.  Hemolysis-associated priapism in sickle cell disease.

Authors:  Vikki G Nolan; Diego F Wyszynski; Lindsay A Farrer; Martin H Steinberg
Journal:  Blood       Date:  2005-06-28       Impact factor: 22.113

8.  Biological activity of nitric oxide in the plasmatic compartment.

Authors:  Xunde Wang; Jose E Tanus-Santos; Christopher D Reiter; Andre Dejam; Sruti Shiva; Reginald D Smith; Neil Hogg; Mark T Gladwin
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-16       Impact factor: 11.205

9.  Sickle cell anemia is associated with reduced nitric oxide bioactivity in peripheral conduit and resistance vessels.

Authors:  Robert T Eberhardt; Lillian McMahon; Stephen J Duffy; Martin H Steinberg; Susan P Perrine; Joseph Loscalzo; Jay D Coffman; Joseph A Vita
Journal:  Am J Hematol       Date:  2003-10       Impact factor: 10.047

Review 10.  No scavenging and the hypertensive effect of hemoglobin-based blood substitutes.

Authors:  John S Olson; Erin W Foley; Corina Rogge; Ah-Lim Tsai; Michael P Doyle; Douglas D Lemon
Journal:  Free Radic Biol Med       Date:  2004-03-15       Impact factor: 7.376

View more
  122 in total

1.  The neonatal circuit: in search of the ultimate solution.

Authors:  Filip De Somer
Journal:  J Extra Corpor Technol       Date:  2012-03

2.  Free hemoglobin induction of pulmonary vascular disease: evidence for an inflammatory mechanism.

Authors:  Paul W Buehler; Jin Hyen Baek; Christina Lisk; Ian Connor; Tim Sullivan; Douglas Kominsky; Susan Majka; Kurt R Stenmark; Eva Nozik-Grayck; Joe Bonaventura; David C Irwin
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2012-06-22       Impact factor: 5.464

3.  Pulmonary hypertension and NO in sickle cell.

Authors:  Mark T Gladwin; Robyn J Barst; Oswaldo L Castro; Victor R Gordeuk; Cheryl A Hillery; Gregory J Kato; Daniel B Kim-Shapiro; Roberto Machado; Claudia R Morris; Martin H Steinberg; Elliott P Vichinsky
Journal:  Blood       Date:  2010-08-05       Impact factor: 22.113

4.  Reversal of hemoglobin-induced vasoconstriction with sustained release of nitric oxide.

Authors:  Pedro Cabrales; George Han; Parimala Nacharaju; Adam J Friedman; Joel M Friedman
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-11-05       Impact factor: 4.733

5.  Association between hemoglobin level and endothelial function in uncomplicated, untreated hypertensive patients.

Authors:  Raffaele Maio; Angela Sciacqua; Rosamaria Bruni; Alessandra Pascale; Giuseppe Carullo; Paola E Scarpino; Desirée Addesi; Ines Spinelli; Giulia Galiano Leone; Francesco Perticone
Journal:  Clin J Am Soc Nephrol       Date:  2010-11-11       Impact factor: 8.237

Review 6.  The potential adverse effects of haemolysis.

Authors:  Francesca Rapido
Journal:  Blood Transfus       Date:  2017-05       Impact factor: 3.443

7.  Haemoglobinuria is associated with chronic kidney disease and its progression in patients with sickle cell anaemia.

Authors:  Santosh L Saraf; Xu Zhang; Tamir Kanias; James P Lash; Robert E Molokie; Bharvi Oza; Catherine Lai; Julie H Rowe; Michel Gowhari; Johara Hassan; Joseph Desimone; Roberto F Machado; Mark T Gladwin; Jane A Little; Victor R Gordeuk
Journal:  Br J Haematol       Date:  2013-12-12       Impact factor: 6.998

8.  Transfusion of older stored blood worsens outcomes in canines depending on the presence and severity of pneumonia.

Authors:  Dong Wang; Irene Cortés-Puch; Junfeng Sun; Steven B Solomon; Tamir Kanias; Kenneth E Remy; Jing Feng; Meghna Alimchandani; Martha Quezado; Christine Helms; Andreas Perlegas; Mark T Gladwin; Daniel B Kim-Shapiro; Harvey G Klein; Charles Natanson
Journal:  Transfusion       Date:  2014-03-03       Impact factor: 3.157

9.  Cell-Free Plasma Hemoglobin and Male Gender Are Risk Factors for Acute Kidney Injury in Low Risk Children Undergoing Cardiopulmonary Bypass.

Authors:  Nahmah Kim-Campbell; Catherine Gretchen; Clifton Callaway; Kathryn Felmet; Patrick M Kochanek; Timothy Maul; Peter Wearden; Mahesh Sharma; Melita Viegas; Ricardo Munoz; Mark T Gladwin; Hülya Bayir
Journal:  Crit Care Med       Date:  2017-11       Impact factor: 7.598

10.  Angeli's salt counteracts the vasoactive effects of elevated plasma hemoglobin.

Authors:  Steven B Solomon; Landon Bellavia; Daniel Sweeney; Barbora Piknova; Andreas Perlegas; Christine C Helms; Gabriela A Ferreyra; S Bruce King; Nicolaas J H Raat; Steven J Kern; Junfeng Sun; Linda C McPhail; Alan N Schechter; Charles Natanson; Mark T Gladwin; Daniel B Kim-Shapiro
Journal:  Free Radic Biol Med       Date:  2012-10-23       Impact factor: 7.376

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.